EMAIL THIS PAGE TO A FRIEND

Surgery today

Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus.


PMID 27130464

Abstract

The aim of this study was to identify the biomarkers associated with chemotherapeutic efficacy and long-term survival for patients with advanced squamous cell carcinoma of the esophagus (SCCE) who had received neoadjuvant chemotherapy with docetaxel and cisplatin plus 5-fluorouracil (NAC-DCF). This study included 45 patients with advanced SCCE who received NAC-DCF between 2008 and 2012. The NAC-DCF was conducted as a phase II study (UMIN000007408). The expressions of excision repair cross-complementing-1 (ERCC1), class III beta-tubulin, breast cancer susceptibility gene I (BRCA1), and thymidylate synthase were investigated simultaneously in the pre-treatment endoscopic tumor biopsy samples. A multivariate logistic regression analysis indicated that pathological responses were significantly associated with tumors with low ERCC1 expression (Pxa0=xa00.016) and with tumors with high BRCA1 expression (Pxa0=xa00.030). The multivariate Cox proportional hazard model analysis for relapse-free survival revealed high BRCA1 expression (Pxa0=xa00.031, hazards ratio 4.39) as the factor associated with survival. Low ERCC1 expression and high BRCA1 expression in patients with SCCE were associative biomarkers for chemotherapeutic efficacy. High BRCA1 expression was considered the factor associated with survival. These findings may be helpful for tailoring chemotherapy.